Betahistine is not available as an FDA-approved medication in the United States because the agency revoked its approval in 1970 after finding that the original application contained unsubstantiated information about patients in the efficacy studies. Since then, no company has successfully brought it back through the approval process, largely because the clinical evidence for betahistine remains surprisingly weak by modern standards. The drug is, however, widely prescribed in dozens of other countries for Ménière’s disease symptoms like vertigo, tinnitus, and hearing loss.
The 1970 FDA Withdrawal
Betahistine was originally sold in the US under the brand name Serc. The FDA approved it to treat vertigo in patients with Ménière’s disease, but in 1970 the Commissioner of the FDA withdrew that approval. The reason: the agency discovered that the original submission contained unsubstantiated information about some of the patients in the clinical trials that had supported its approval. In regulatory terms, the drug was found to “lack substantial evidence of effectiveness” for its approved use.
This happened during a broader era of FDA reform. In the years following the 1962 amendments to federal drug law, the agency was systematically re-evaluating older drugs that had been approved before rigorous efficacy standards were in place. Betahistine was one of the casualties of that review. Once withdrawn, a drug doesn’t simply return to the market. A manufacturer would need to file a new application supported by modern clinical trials, which is expensive and time-consuming.
The Evidence Problem
The deeper issue is that, more than 50 years later, high-quality evidence for betahistine still hasn’t materialized. This is the main reason no pharmaceutical company has invested in bringing it back through the FDA approval process.
The most rigorous test to date was the BEMED trial, a long-term, multicenter, double-blind, placebo-controlled study. It compared two doses of betahistine (48 mg and 144 mg daily) against a placebo over nine months. The result was clear: the rate of Ménière’s attacks did not differ between the three groups. Both betahistine doses were statistically indistinguishable from placebo. Attack rates, vestibular function, hearing tests, and quality of life scores all showed the same pattern. The researchers concluded there was no clear evidence that patients experienced a meaningful reduction in attacks compared to those taking a sugar pill.
One notable detail: all three groups, including placebo, saw a significant drop in attack frequency over the study period. Monthly attacks fell by about 24% across the board. This strong placebo response may partly explain why so many patients and doctors believe betahistine works. If you start taking it during a bad stretch of symptoms and those symptoms improve (as they often do naturally with Ménière’s disease), it’s easy to credit the medication.
The most recent Cochrane review of betahistine for Ménière’s disease reached a similar conclusion. After reviewing seven randomized controlled trials involving 548 participants, the reviewers found they couldn’t even combine the studies into a meaningful analysis because the trials used different outcome measures, different follow-up periods, and different assessment methods. Their summary: “It is unclear whether betahistine has an effect on vertigo symptoms.”
How Betahistine Is Supposed to Work
Betahistine is a synthetic compound related to histamine. It gently activates one type of histamine receptor while more strongly blocking another. The net effect, at least in animal studies, is increased blood flow to the inner ear. For a long time, the leading theory was that this improved circulation could relieve the fluid pressure buildup that causes Ménière’s symptoms.
More recent research suggests the picture is more complex, involving effects on blood vessels in the brain and inner ear through multiple receptor types. The drug also appears to influence the autonomic nervous system’s control of blood vessel tone. These mechanisms are well-documented in laboratory settings, but translating them into proven clinical benefit in humans has been the sticking point.
Why Other Countries Still Prescribe It
Despite the weak trial evidence, betahistine remains a standard prescription in much of Europe, Asia, and other regions. The UK’s National Health Service lists it as a treatment for Ménière’s symptoms including vertigo, tinnitus, hearing loss, and nausea. The typical regimen is three times daily, spaced six to eight hours apart.
This gap between US and international practice comes down to different regulatory philosophies and timing. Many countries approved betahistine decades ago under less stringent evidence requirements and have kept it available because it has an excellent safety profile, is inexpensive, and patients report subjective improvement. The BEMED trial’s placebo-controlled results, published in 2016, haven’t led to widespread withdrawal elsewhere, partly because doctors and patients in those countries have long experience with the drug and Ménière’s disease has few good treatment options regardless.
How Some US Patients Get It Anyway
There is a legal workaround. Under federal compounding pharmacy laws, pharmacists can prepare customized medications for individual patients, even using bulk drug substances that aren’t in FDA-approved products. Betahistine falls into a gray area here. The FDA has acknowledged that betahistine dihydrochloride is a “chemically well characterized histamine analog” and has considered whether to formally add it to the list of approved compounding ingredients. In practice, some US compounding pharmacies do prepare betahistine with a doctor’s prescription, though availability varies and costs are typically higher than in countries where manufactured tablets are sold.
Interestingly, even the Mayo Clinic’s treatment page for Ménière’s disease mentions betahistine alongside diuretics as an option, noting that it “eases vertigo symptoms by improving blood flow to the inner ear.” This reflects the reality that some US physicians do prescribe compounded betahistine, particularly for patients who haven’t responded to other treatments.
What US Doctors Use Instead
Without betahistine as a standard option, Ménière’s disease management in the US leans on a different toolkit. The first-line approach typically combines dietary salt restriction with diuretics, medications that reduce fluid retention throughout the body. The theory is that lowering overall fluid volume also reduces the excess fluid in the inner ear that drives Ménière’s symptoms. Anti-nausea medications are used during acute vertigo attacks.
For patients who don’t respond to conservative treatment, the options escalate to procedures like injections of medication through the eardrum or, in severe cases, surgery. None of these alternatives have dramatically stronger evidence than betahistine, which is part of the frustration for both patients and clinicians. Ménière’s disease remains genuinely difficult to treat, and the strong placebo response seen in trials makes it hard to prove any intervention works beyond what the body does on its own over time.